Get the Stockscreener App
72.92
0.08%
0.06
After Hours:
72.92
Avidity Biosciences Inc stock is traded at $72.92, with a volume of 3.70M.
It is up +0.08% in the last 24 hours and up +0.44% over the past month.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
See More
Previous Close:
$72.86
Open:
$72.81
24h Volume:
3.70M
Relative Volume:
1.68
Market Cap:
$11.26B
Revenue:
$10.73M
Net Income/Loss:
$-455.74M
P/E Ratio:
-20.50
EPS:
-3.5569
Net Cash Flow:
$-502.70M
1W Performance:
+0.07%
1M Performance:
+0.44%
6M Performance:
+57.32%
1Y Performance:
+134.32%
1-Day Range:
$72.81
$73.05
1-Week Range:
$72.73
$73.05
52-Week Range:
$21.51
$73.06
Avidity Biosciences Inc Stock (RNA) Company Profile
Name
Avidity Biosciences Inc
Sector
Industry
Phone
858-401-7900
Address
3020 CALLAN ROAD, SAN DIEGO, CA
Compare RNA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNA
Avidity Biosciences Inc
|
72.92 | 11.26B | 10.73M | -455.74M | -502.70M | -3.5569 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.01 | 121.15B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.04 | 82.43B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
826.25 | 52.25B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.35 | 44.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
370.64 | 40.07B | 4.98B | 69.60M | 525.67M | 0.5198 |
Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-17-25 | Initiated | Roth Capital | Buy |
| Jul-10-25 | Resumed | Goldman | Buy |
| Jun-24-25 | Initiated | Bernstein | Outperform |
| Jun-17-25 | Initiated | Wolfe Research | Outperform |
| Jun-11-25 | Initiated | Raymond James | Strong Buy |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Mar-12-25 | Initiated | BMO Capital Markets | Outperform |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-20-24 | Initiated | H.C. Wainwright | Buy |
| Nov-26-24 | Initiated | RBC Capital Mkts | Outperform |
| Sep-24-24 | Initiated | Goldman | Buy |
| Aug-28-24 | Initiated | Barclays | Overweight |
| May-03-24 | Initiated | BofA Securities | Buy |
| Mar-14-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-22-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-31-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Jul-20-22 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-22 | Initiated | Raymond James | Strong Buy |
| Sep-07-21 | Initiated | Evercore ISI | Outperform |
| Jun-17-21 | Initiated | Needham | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Jul-07-20 | Initiated | Cowen | Outperform |
| Jul-07-20 | Initiated | Credit Suisse | Outperform |
| Jul-07-20 | Initiated | SVB Leerink | Outperform |
| Jul-07-20 | Initiated | Wells Fargo | Overweight |
View All
Avidity Biosciences Inc Stock (RNA) Latest News
Avidity postpones stockholder meeting, sets merger dates By Investing.com - Investing.com Australia
Avidity Biosciences, Inc. SEC 10-K Report - TradingView
Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders - BioSpace
Avidity Biosciences, Inc. (RNA) Stock Analysis: Exploring Growth Potential Amidst 434% Revenue Surge - DirectorsTalk Interviews
Avidity Biosciences Advances Toward Novartis Merger Completion - TipRanks
Avidity Biosciences to adjourn Feb 23 special meeting; Distribution expected Feb 26, Merger close Feb 27 - TradingView
Avidity postpones stockholder meeting, sets merger dates - Investing.com
Biotech delays key vote as Atrium stock distribution, Novartis merger approach - Stock Titan
Avoro Capital Advisors LLC Increases Stake in Avidity Biosciences Inc - GuruFocus
Fiera Capital Corp Has $52.39 Million Position in Avidity Biosciences, Inc. $RNA - MarketBeat
Avidity Biosciences, Inc. $RNA Shares Acquired by Envestnet Asset Management Inc. - MarketBeat
Aberdeen Group plc Buys 25,000 Shares of Avidity Biosciences, Inc. $RNA - MarketBeat
Avidity’s myotonic dystrophy drug shows promising results in trial - Investing.com Australia
Readystate Asset Management LP Makes New Investment in Avidity Biosciences, Inc. $RNA - MarketBeat
HC Wainwright & Co. Downgrades Avidity Biosciences (RNA) - MSN
Assetmark Inc. Buys 21,507 Shares of Avidity Biosciences, Inc. $RNA - MarketBeat
Avidity Biosciences (RNA) to Release Earnings on Thursday - MarketBeat
Avidity Biosciences Reports Del-desiran Clinical Trial Results - Intellectia AI
Avidity’s myotonic dystrophy drug shows promising results in trial By Investing.com - Investing.com South Africa
The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1 - Finviz
The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA® Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1 - PR Newswire
Avidity Biosciences reports data from DMD treatment trials - MSN
Avidity Biosciences, Inc. (RNA) Stock Analysis: Exploring Growth Potential In RNA Therapeutics - DirectorsTalk Interviews
Avidity Biosciences Acquired by Novartis for $72 per Share - Intellectia AI
Allianz Asset Management GmbH Invests $632,000 in Avidity Biosciences, Inc. $RNA - MarketBeat
What drives Avidity Biosciences Inc.’s stock price2025 Dividend Review & Daily Profit Maximizing Tips - mfd.ru
Facioscapulohumeral Muscular Dystrophy Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Dyne Therapeutics, miRecule, Avidity Biosciences, aTyr Pharma, Fulcrum Therapeutics - Barchart.com
Facioscapulohumeral Muscular Dystrophy Market: High-Growth - openPR.com
Does Avidity Biosciences Inc. have strong EBITDA marginsJuly 2025 Trends & Free High Return Stock Watch Alerts - mfd.ru
Is Avidity Biosciences Inc. stock near bottom after declineProduct Launch & Detailed Earnings Play Alerts - mfd.ru
Why Avidity Biosciences Inc. stock is recommended by analystsJuly 2025 Chart Watch & Smart Investment Allocation Tips - mfd.ru
Volume Report: How does Avidity Biosciences Inc compare to its peersAnalyst Downgrade & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Avidity Biosciences, Inc. $RNA Shares Acquired by Candriam S.C.A. - MarketBeat
Avidity Biosciences prices $600M stock offering - MSN
Avidity Biosciences, Inc. (NASDAQ:RNA) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE) and Avidity Biosciences (RNA) - The Globe and Mail
(RNA) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Key facts: JPMorgan raises concerns on Novartis outlook; Novartis to acquire Avidity - TradingView
Avidity Biosciences Announces Expected Record Date for Spin-Off - TradingView
Avidity Biosciences stock hits all-time high at 72.74 USD By Investing.com - Investing.com Australia
Avidity Biosciences receives FTC clearance for Novartis merger - MSN
Novartis (NVS) Acquisition of Avidity Biosciences Moves Forward - GuruFocus
Avidity Biosciences Sets February 15, 2026 as Record Date for Planned Spin-Off - geneonline.com
Avidity holders to get Atrium cardiology SpinCo shares in Novartis deal - stocktitan.net
Avidity Biosciences says record date set for February 12, 2026 for spin-off - marketscreener.com
Avidity Biosciences Says Record Date Set For February 12, 2026 For Spin-Off - TradingView
Avidity Biosciences Announces Share Distribution for Spin-Off - Intellectia AI
Avidity Biosciences (NASDAQ:RNA) Hits New 12-Month HighHere's What Happened - MarketBeat
Avidity Biosciences stock hits all-time high at 72.74 USD - Investing.com
New York State Common Retirement Fund Purchases 120,365 Shares of Avidity Biosciences, Inc. $RNA - MarketBeat
Atle Fund Management AB Makes New Investment in Avidity Biosciences, Inc. $RNA - MarketBeat
Avidity Biosciences Inc Stock (RNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.25%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):